About carfilzomib
Proteasome inhibitor anticancer medicine
Used for
- Treats multiple myeloma, usually with other medicines, in adults whose disease has returned or not responded.
Usual adult dose
Usually 20 mg/m² by intravenous infusion initially, increasing to 27, 56, or 70 mg/m² depending on the treatment combination and schedule.
Common side effects
- Fatigue, fever, nausea, diarrhoea, or breathlessness
- Low blood cell counts and increased infection risk
- High blood pressure
- Heart, kidney, or lung problems
Important warnings
- Can cause serious heart failure, heart attack, or irregular heartbeat.
- May cause severe lung reactions, kidney injury, bleeding, or infections.
- Blood clots and tumour lysis syndrome can occur.
- Treatment requires monitoring and is given by specialist teams.
Pregnancy
Can harm an unborn baby. Pregnancy testing and effective contraception are advised during treatment and for one month afterward for women; men should use contraception for three months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for two weeks after the final dose.
Interactions
- Some medicines can affect carfilzomib exposure; report all medicines and supplements to the treatment team.
- Strong CYP3A inducers, such as rifampicin, may reduce carfilzomib exposure.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.